Clinical Analysis of Trastuzumab-Targeted and Chemotherapy Treatment for Breast Cancer Patients  

作　　者：Ying Liang 

机构地区：[1]Department of Thyroid and Breast Surgery,The Second Affiliated Hospital of Kunming Medical University,Kunming 650000,Yunnan Province,China

出　　处：《Proceedings of Anticancer Research》2024年第6期73-79,共7页抗癌研究

基　　金：Yunnan Provincial Department of Education Scientific Research Fund Project“Research on the Construction of Antibody-Drug Conjugate MMAF-Trastuzumab and Its Biological Function in Inhibiting Breast Cancer”(Project No.2024J0227)。

摘　　要：Objective: To explore the clinical effectiveness and safety of trastuzumab combined with chemotherapy in breast cancer patients. Methods: Eighty patients with postoperative local recurrence of breast cancer were divided into a control group (chemotherapy only) and an observation group (chemotherapy plus trastuzumab-targeted therapy). The clinical efficacy, adverse reactions, and complications were compared between groups. Results: The overall effective rate of clinical treatment in the observation group was higher than that in the control group (P < 0.05). The incidence of adverse reactions showed no difference between the groups (P > 0.05), while the complication rate was significantly lower in the observation group (P < 0.05). Conclusion: Trastuzumab-targeted therapy combined with chemotherapy can significantly improve clinical treatment outcomes for breast cancer patients, reduce the risk of complications, and maintain good safety, making it suitable for clinical promotion.

关 键 词：Breast cancer TRASTUZUMAB Targeted therapy CHEMOTHERAPY Clinical treatment efficacy 

分 类 号：R73[医药卫生—肿瘤]